| Identification | Back Directory | [Name]
Tricyclo[3.3.1.13,7]decan-1-amine, 3-(2-fluoroethyl)- | [CAS]
1639210-26-6 | [Synonyms]
Fluoroethylnormemantine
Tricyclo[3.3.1.13,7]decan-1-amine, 3-(2-fluoroethyl)- | [Molecular Formula]
C12H20FN | [MOL File]
1639210-26-6.mol | [Molecular Weight]
197.29 |
| Chemical Properties | Back Directory | [Boiling point ]
261.8±5.0 °C(Predicted) | [density ]
1.098±0.06 g/cm3(Predicted) | [form ]
Oil | [pka]
10.62±0.40(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Description]
FFENM is a novel potent neuroprotective agent for treatment of Alzheimer's disease (AD), targeting NMDA receptor. | [Uses]
Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects[1][2][3]. | [in vivo]
Fluoroethylnormemantine (0.1-10 mg/kg; a single i.p.) shows anti-amnesic effects on Aβ?25-35-induced learning impairments in mice[1].
Fluoroethylnormemantine (0.1-10 mg/kg; i.p. once daily for 7 days) attenuates Aβ?25-35-induced behavioral deficits, neuroinflammation, oxidative stress, apoptosis, and cell loss in mice[1].
Fluoroethylnormemantine (1-20 mg/kg; a single injection) decreases behavioral despair in the forced swim test (FST) and reduces fear behavior in the cued fear conditioning (FC) and extinction training in rats[2]. | Animal Model: | Male Swiss CD-1 mice (7-9 weeks) were injected with Aβ25-35[1] | | Dosage: | 0.1, 0.3, 1, 3, 10 mg/kg | | Administration: | I.p. 30 minutes before the behavioral tests | | Result: | Attenuated Aβ?25-35-induced spontaneous alternation deficit, passive avoidance deficit, and novel object exploration deficit. |
| [IC 50]
NMDA Receptor | [References]
[1] Couly S, et, al. Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer's Disease. Int J Neuropsychopharmacol. 2021 Feb 15;24(2):142-157. DOI:10.1093/ijnp/pyaa075
[2] Chen BK, et, al. Fluoroethylnormemantine, a novel derivative of memantine, facilitates extinction learning without sensorimotor deficits. Int J Neuropsychopharmacol. 2021 Feb 25;pyab007. DOI:10.1093/ijnp/pyab007
[3] Chen BK, et, al. Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior. Biological Psychiatry. 2021 May 9. |
|
|